[1]
|
Motzer, R.J., Jonasch, E., Agarwal, N., et al. (2022) Kidney Cancer, Version 3. 2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 71-90.
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
Moch, H., Cubilla, A.L., Humphrey, P.A., Reuter, V.E. and Ulbright, T.M. (2016) The 2016 Who Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 70, 93-105. https://doi.org/10.1016/j.eururo.2016.02.029
|
[4]
|
Bukowski, R.M. (1997) Natural History and Therapy of Metastatic Renal Cell Carcinoma. Cancer, 80, 1198-1220. https://doi.org/10.1002/(sici)1097-0142(19971001)80:7<1198::aid-cncr3>3.0.co;2-h
|
[5]
|
National Comprehensive Cancer Network (2023) Kidney Cancer (v.1.2024). https://www.nccnchina.org.cn/guide/detail/406
|
[6]
|
Ahmed, R. and Ornstein, M.C. (2023) Targeting HIF-2 Alpha in Renal Cell Carcinoma. Current Treatment Options in Oncology, 24, 1183-1198. https://doi.org/10.1007/s11864-023-01106-y
|
[7]
|
曹铮, 冯林, 冯晓莉. 缺氧相关的miRNA-210在肿瘤中的研究进展[J]. 肿瘤防治研究, 2018, 45(7): 500-504.
|
[8]
|
Xu, R., Wang, K., Rizzi, J.P., et al. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. Journal of Medicinal Chemistry, 62, 6876-6893. https://doi.org/10.1021/acs.jmedchem.9b00719
|
[9]
|
Choueiri, T.K., Bauer, T.M., Papadopoulos, K.P., Plimack, E.R., Merchan, J.R., McDermott, D.F., et al. (2021) Inhibition of Hypoxia-Inducible Factor-2α in Renal Cell Carcinoma with Belzutifan: A Phase 1 Trial and Biomarker Analysis. Nature Medicine, 27, 802-805. https://doi.org/10.1038/s41591-021-01324-7
|
[10]
|
Musleh Ud Din, S., Streit, S.G., Huynh, B.T., Hana, C., Abraham, A. and Hussein, A. (2024) Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer. International Journal of Molecular Sciences, 25, Article No. 2060. https://doi.org/10.3390/ijms25042060
|
[11]
|
Yue, Y., Tang, Y., Huang, H., Zheng, D., Liu, C., Zhang, H., et al. (2023) VBP1 Negatively Regulates Chip and Selectively Inhibits the Activity of Hypoxia-Inducible Factor (HIF)-1α but Not HIF-2α. Journal of Biological Chemistry, 299, Article ID: 104829. https://doi.org/10.1016/j.jbc.2023.104829
|
[12]
|
Peng, S., Wang, Z., Tang, P., Wang, S., Huang, Y., Xie, Q., et al. (2023) PHF8-GLUL Axis in Lipid Deposition and Tumor Growth of Clear Cell Renal Cell Carcinoma. Science Advances, 9, eadf3566. https://doi.org/10.1126/sciadv.adf3566
|
[13]
|
Zhang, X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., et al. (2022) TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Cancer Research, 82, 2097-2109. https://doi.org/10.1158/0008-5472.can-21-3013
|
[14]
|
Rivas, S., Silva, P., Reyes, M., Sepúlveda, H., Solano, L., Acuña, J., et al. (2020) The RabGEF ALS2 Is a Hypoxia Inducible Target Associated with the Acquisition of Aggressive Traits in Tumor Cells. Scientific Reports, 10, Article No. 22302. https://doi.org/10.1038/s41598-020-79270-6
|
[15]
|
Gu, X., Meng, H., Wang, J., Wang, R., Cao, M., Liu, S., et al. (2021) Hypoxia Contributes to Galectin-3 Expression in Renal Carcinoma Cells. European Journal of Pharmacology, 890, Article ID: 173637. https://doi.org/10.1016/j.ejphar.2020.173637
|
[16]
|
Liu, G., Lu, Y., Li, L., Jiang, T., Chu, S., Hou, P., et al. (2020) The Kinesin Motor Protein KIF4A as a Potential Therapeutic Target in Renal Cell Carcinoma. Investigational New Drugs, 38, 1730-1742. https://doi.org/10.1007/s10637-020-00961-y
|
[17]
|
Hong, K., Hu, L., Liu, X., Simon, J.M., Ptacek, T.S., Zheng, X., et al. (2020) Usp37 Promotes Deubiquitination of HIF2α in Kidney Cancer. Proceedings of the National Academy of Sciences, 117, 13023-13032. https://doi.org/10.1073/pnas.2002567117
|
[18]
|
Liu, C., Liu, L., Wang, K., Li, X., Ge, L., Ma, R., et al. (2020) VHL-Hif-2α Axis-Induced SMYD3 Upregulation Drives Renal Cell Carcinoma Progression via Direct Trans-Activation of EGFR. Oncogene, 39, 4286-4298. https://doi.org/10.1038/s41388-020-1291-7
|
[19]
|
Fan, Y., Ou, L., Fan, J., Li, L., Wu, X., Luo, C., et al. (2019) HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1α/NF-κB Signaling Pathway. Urology, 127, 61-67. https://doi.org/10.1016/j.urology.2018.11.033
|
[20]
|
Huang, R.R., Chen, Z., Kroeger, N., Pantuck, A., Said, J., Kluger, H.M., et al. (2024) CD70 Is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 22, 347-353. https://doi.org/10.1016/j.clgc.2023.12.003
|
[21]
|
Li, X., Wu, Y., Xiao, Z., Liu, Y., Wang, C., Zhou, L., et al. (2024) Long Non-Coding RNA HIF1A-AS2 Promotes Carcinogenesis by Enhancing Gli1-Mediated HIF1α Expression in Clear Cell Renal Cell Carcinoma. Pathology—Research and Practice, 253, Article ID: 154984. https://doi.org/10.1016/j.prp.2023.154984
|
[22]
|
Singh, A., Choudhury, S.D., Singh, P., Singh, V.V., Singh, S.N. and Sharma, A. (2022) KCMF1 Regulates Autophagy and Ion Channels’ Function in Renal Cell Carcinoma: A Future Therapeutic Target. Journal of Cancer Research and Clinical Oncology, 149, 5617-5626. https://doi.org/10.1007/s00432-022-04507-y
|
[23]
|
Liao, M., Li, Y., Xiao, A., Lu, Q., Zeng, H., Qin, H., et al. (2022) HIF-2α-Induced Upregulation of CD36 Promotes the Development of CCRCC. Experimental Cell Research, 421, Article ID: 113389. https://doi.org/10.1016/j.yexcr.2022.113389
|
[24]
|
Panowski, S.H., Srinivasan, S., Tan, N., et al. (2022) Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. Cancer Research, 82, 2610-2624. https://doi.org/10.1158/0008-5472.CAN-21-2931
|